news
New “atlas” charts how antibodies attack COVID-19 Spike variants
A new “atlas” has been created in the US that charts how 152 different antibodies attack the SARS-CoV-2 Spike protein.
List view / Grid view
Proteomics
article
Recognition of phosphohistidine-containing peptides by antibodies
In this article, Dr Rajasree Kalagiri explains research into the use of monoclonal antibodies for the differential recognition of phosphohistidine-containing peptides.
whitepaper
Application note: High-throughput IgG quantitation platform for clone screening during drug discovery and development
Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.
article
How engineered RNA binding proteins delivered in vivo by gene therapy could treat myotonic dystrophy
In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.
news
Anticoagulant drug a possible strategy to treat COVID-19 variants
Researchers in Australia have discovered a new site on the COVID-19 Spike protein that could be targeted by an anticoagulant drug.
news
Protein activation discovery could widen access to cancer immunotherapy
The activation of the protein p53 was shown to boost immune responses against cancer tumours in mice in a new study, potentially widening access to immunotherapy.
whitepaper
Infographic: Top reasons to select Bethyl bulk antibodies
10 reasons to choose Bethyl antibodies and reagents from Fortis Life Sciences for your applications.
whitepaper
ebook: Optimise your high value cell lines
As interest in biotherapeutic proteins grows, the need to reduce cell line development costs and the time to market is more critical than ever.
whitepaper
Guide: Eight tips for ensuring a successful ELISA
Learn quick technical tips to optimise your ELISA workflow, including how to: select the right ELISA kit, avoid contamination and normalise data.
news
Structural changes in SARS-CoV-2 Alpha and Beta variants revealed
A study has uncovered previously unknown properties of the Spike protein from the SARS-CoV-2 Alpha and Beta variants.
news
New technique developed for identifying therapeutic nanobodies
Researchers have used a new method for discovering nanobodies to identify potential therapeutics against SARS-CoV-2 infection.
news
Dual antibodies effective against SARS-CoV-2 variants in animal study
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
article
Covalent fragment screening in cell-based phenotypic models of disease: a collaborative approach
The application of chemical perturbation approaches in phenotypic models is often used to identify protein targets for therapeutic discovery. Increasingly, small molecule fragments which covalently bind to their protein targets are being used to explore the druggable proteome and the resulting fragment‑protein interactions are characterised by chemoproteomic techniques. In this…
article
Screening for COVID-19 drugs
With the COVID-19 pandemic ongoing, new therapeutic drugs to combat SARS-CoV-2 are still required. In this article, Professor Arvind Patel from the Medical Research Council (MRC) – Centre for Virus Research (CVR) at the University of Glasgow spoke with Drug Target Review’s Victoria Rees to discuss the work being done…
article
Better therapeutic antibodies by design
The binding specificity and high binding affinity of therapeutic antibodies makes them an ideal therapy for treating a wide range of human disorders. Advancements in antibody technologies have resulted in huge development success along with a boost in novel and improved treatment strategies. However, specific challenges and considerations are faced…
